Menu
 
Research menu
Jump to menu

Publications:  Prof David Baker

Baker D, Amor S(2019). Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model. Annals of Clinical and Translational Neurology
10.1002/acn3.792
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58838
Batcheller L, Baker D(2019). Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer?. Journal of the Neurological Sciences vol. 404, 19-28.
10.1016/j.jns.2019.07.009
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58685
Tabatabaee S, Baker D, Selwood DL, Whalley BJ, Stephens GJ(2019). The Cannabinoid-Like Compound, VSN16R, Acts on Large Conductance, Ca2+-Activated K+ Channels to Modulate Hippocampal CA1 Pyramidal Neuron Firing. Pharmaceuticals (Basel) vol. 12, (3)
10.3390/ph12030104
Baker D, Jacobs BM, Gnanapavan S, Schmierer K, Giovannoni G(2019). Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis. Mult Scler Relat Disord vol. 35, 19-25.
10.1016/j.msard.2019.06.030
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58602
Baker D, Pryce G, Herrod SS, Schmierer K(2019). Potential mechanisms of action related to the efficacy and safety of cladribine. Mult Scler Relat Disord vol. 30, 176-186.
10.1016/j.msard.2019.02.018
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55609
Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Campion T, Adams A, Turner BP et al.(2019). Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies. Mult Scler Relat Disord vol. 27, 247-253.
10.1016/j.msard.2018.11.001
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55054
Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K(2018). Cladribine: mechanisms and mysteries in multiple sclerosis. J Neurol Neurosurg Psychiatry vol. 89, (12) 1266-1271.
10.1136/jnnp-2017-317411
https://qmro.qmul.ac.uk/xmlui/handle/123456789/42426
Dubuisson N, Marta M, Gnanapavan S, Turner B, Baker D, Thomson A, Schmierer K, Giovannoni G(2018). Inclusion criteria used in trials of people with progressive multiple sclerosis. Mult Scler1352458518803769-1352458518803769.
10.1177/1352458518803769
https://qmro.qmul.ac.uk/xmlui/handle/123456789/49361
BAKER D, GIOVANNONI G, PRYCE G, AMOR S, SCHMIERER K(2018). Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis. Brain
10.1093/brain/awy239
https://qmro.qmul.ac.uk/xmlui/handle/123456789/45063
BO X, GUSHCHINA S, PRYCE G, YIP P, Wu D, PALLIER P, GIOVANNONI G, BAKER D(2018). Increased expression of colony-stimulating factor-1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss. Glia
10.1002/glia.23464
https://qmro.qmul.ac.uk/xmlui/handle/123456789/43866
BO XUENONG, GUSHCHINA S, PRYCE G, YIP P, WU D, PALLIER P, GIOVANNONI G, BAKER D(2018). Increased expression of colony‐stimulating factor‐1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss. Glia vol. 66, (10) 2108-2125.
10.1002/glia.23464
https://qmro.qmul.ac.uk/xmlui/handle/123456789/43866
Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al.(2018). Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine. Mult Scler Relat Disord vol. 24, 20-27.
10.1016/j.msard.2018.05.010
https://qmro.qmul.ac.uk/xmlui/handle/123456789/42224
BAKER D, Pryce, G(2018). Oligoclonal bands in multiple sclerosis; functional significance and therapeutic implications. Does the specificity matter?. multiple sclerosis and related disorders
10.1016/j.msard.2018.07.03
https://qmro.qmul.ac.uk/xmlui/handle/123456789/43565
Mao Z, Álvarez-Gonzalez C, De Trane S, Yildiz O, Albor C, Doctor G, Soon D, Pepper G et al.(2018). Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?. Multiple Sclerosis Journal - Experimental, Translational and Clinical vol. 4, (2) 2055217318783767-2055217318783767.
10.1177/2055217318783767
https://qmro.qmul.ac.uk/xmlui/handle/123456789/43785
Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S et al.(2018). Alemtuzumab depletion failure can occur in multiple sclerosis. Immunology vol. 154, (2) 253-260.
10.1111/imm.12879
https://qmro.qmul.ac.uk/xmlui/handle/123456789/31849
Petrova N, Carassiti D, Altmann DR, Baker D, Schmierer K(2018). Axonal loss in the multiple sclerosis spinal cord revisited. Brain Pathol vol. 28, (3) 334-348.
10.1111/bpa.12516
https://qmro.qmul.ac.uk/xmlui/handle/123456789/22903
Ceronie B, Jacobs BM, Baker D, Dubuisson N, Mao Z, Ammoscato F, Lock H, Longhurst HJ et al.(2018). Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J Neurol vol. 265, (5) 1199-1209.
10.1007/s00415-018-8830-y
https://qmro.qmul.ac.uk/xmlui/handle/123456789/36729
Ruz-Maldonado I, Pingitore A, Liu B, Atanes P, Huang GC, Baker D, Alonso FJ, Bermúdez-Silva FJ et al.(2018). LH‐21 and abnormal cannabidiol improve β‐cell function in isolated human and mouse islets through GPR55‐dependent and ‐independent signalling. Diabetes Obes Metab vol. 20, (4) 930-942.
10.1111/dom.13180
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58997
Dubuisson N, Baker D, Thomson A, Marta M, Gnanapavan S, Turner B, Giovannoni G, Schmierer K(2017). Disease modification in advanced MS: Focus on upper limb function. Mult Scler vol. 23, (14) 1956-1957.
10.1177/1352458517717811
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25093
Puentes F, van der Star BJ, Boomkamp SD, Kipp M, Boon L, Bosca I, Raffel J, Gnanapavan S et al.(2017). Neurofilament light as an immune target for pathogenic antibodies. Immunology vol. 152, (4) 580-588.
10.1111/imm.12797
https://qmro.qmul.ac.uk/xmlui/handle/123456789/36726
Pryce G, Baker D(2017). Antidote to cannabinoid intoxication: the CB1 receptor inverse agonist, AM251, reverses hypothermic effects of the CB1 receptor agonist, CB-13, in mice. Br J Pharmacol vol. 174, (21) 3790-3794.
10.1111/bph.13973
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25739
Baker D, Giovannoni G, Schmierer K(2017). Marked neutropenia: significant but rare in people with multiple sclerosis after alemtuzumab treatment. Multiple Sclerosis and Related Disorders
10.1016/j.msard.2017.09.028
https://qmro.qmul.ac.uk/xmlui/handle/123456789/50563
Dubuisson N, Bauer A, Buckley M, Gilbert R, Paterson A, Marta M, Gnanapavan S, Turner B et al.(2017). Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. Mult Scler Relat Disord vol. 17, 172-176.
10.1016/j.msard.2017.08.002
https://qmro.qmul.ac.uk/xmlui/handle/123456789/29763
BAKER D(2017). SPATIAL DISTRIBUTION OF THE CANNABINOID TYPE 1 AND CAPSAICIN RECEPTORS MAY CONTRIBUTE TO THE COMPLEXITY OF THEIR CROSSTALK. Scientific Reports
10.1038/srep33307
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15973
Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K(2017). Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. JAMA Neurol vol. 74, (8) 961-969.
10.1001/jamaneurol.2017.0676
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25508
Afolabi D, Albor C, Zalewski L, Altmann DR, Baker D, Schmierer K(2017). Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler1352458517726380-1352458517726380.
10.1177/1352458517726380
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25832
BAKER D(2017). Big conductance calcium-activated potassium channel openers control spasticity without sedation. British Journal of Pharmcology
10.1111/bph.13889
https://qmro.qmul.ac.uk/xmlui/handle/123456789/53704
Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K(2017). Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm vol. 4, (4)
10.1212/NXI.0000000000000360
https://qmro.qmul.ac.uk/xmlui/handle/123456789/24514
BAKER D, Herrod SS, Alvarez-Gonzalez C, SCHMIERER K, Giovannoni G(2017). Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. JAMA Neurology vol. 74, (8)
10.1001/jamaneurol.2017.0676
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25508
BAKER D, SCHMIERER K, Herrod S, Alvarez Gonzalez C, Zalewski L, Albor C(2017). Both cladribine and alemtuzumab may effect multiple sclerosis via B cell depletion. Neurology: Neuroimmunology and Neuroinflammation vol. 4, (4)
10.​1212/​NXI.​0000000000000360
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23704
Alvarez-Gonzalez C, Adams A, Mathews J, Turner BP, Giovannoni G, Baker D, Schmierer K(2017). Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis. Annals of Clinical and Translational Neurology
10.1002/acn3.410
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23283
Thomson A, Raciborska D, Baker D, Giovannoni G(2017). How to start a blog. Pract Neurol vol. 17, (3) 224-228.
10.1136/practneurol-2017-001597
https://qmro.qmul.ac.uk/xmlui/handle/123456789/56929
von Kutzleben S, Pryce G, Giovannoni G, Baker D(2017). Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis. Immunology vol. 150, (4) 444-455.
10.1111/imm.12696
https://qmro.qmul.ac.uk/xmlui/handle/123456789/19408
Giovannoni G, Cutter G, Pia-Sormani M, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D et al.(2017). Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Multiple Sclerosis and Related Disorders vol. 12, 70-78.
10.1016/j.msard.2017.01.007
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23518
Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K(2017). Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine vol. 16, 41-50.
10.1016/j.ebiom.2017.01.042
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23134
Liu B, Song S, Ruz-Maldonado I, Pingitore A, Huang GC, Baker D, Jones PM, Persaud SJ(2016). GPR55-dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans. Diabetes Obes Metab vol. 18, (12) 1263-1273.
10.1111/dom.12780
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58687
Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Turner BP, Baker D, Gnanapavan S, Marta M, Giovannoni G et al. (2016). TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 87,
10.1136/jnnp-2016-315106.121
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55055
Williams T, Pryce G, Giovannoni G, Selwood D, Baker D (2016). VSN16R-A NOVEL TREATMENT FOR SPASTICITY IN EXPERIMENTAL MULTIPLE SCLEROSIS. vol. 87, is. 12, Abstract: java.sql.Clob org.hibernate.engine.jdbc.WrappedClob java.io.Serializable ,
10.1136/jnnp-2016-315106.162
https://qmro.qmul.ac.uk/xmlui/handle/123456789/29783
Baker D, Anandhakrishnan A, Tuite-Dalton KA, Lockart-Jones H, Middleton RM, Ford DV, Crowe C, Giovannoni G(2016). How to refer to people with disease in research outputs: The disconnection between academic practise and that preferred by people with multiple sclerosis. Mult Scler Relat Disord vol. 10, 127-133.
10.1016/j.msard.2016.09.007
https://qmro.qmul.ac.uk/xmlui/handle/123456789/17765
Peferoen LAN, Breur M, van de Berg S, Peferoen-Baert R, Boddeke EHWGM, van der Valk P, Pryce G, van Noort JM et al.(2016). Ageing and recurrent episodes of neuroinflammation promote progressive experimental autoimmune encephalomyelitis in Biozzi ABH mice. Immunology vol. 149, (2) 146-156.
10.1111/imm.12644
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13480
Agahozo MC, Peferoen L, Baker D, Amor S(2016). CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis – Targeting T or B cells?. Multiple Sclerosis and Related Disorders vol. 9, Article C, 110-117.
10.1016/j.msard.2016.07.011
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15382
Thomson A, Giovannoni G, Marta M, Gnanpavan S, Turner B, Baker D, Schmierer K (2016). Importance of upper limb function in advanced multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22, 676-676.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25226
Rejdak K, Mitosek-Szewczyk K, Prus K, Trzciniecka O, Baker D, Schmierer K, Stelmasiak Z (2016). Induction therapy of relapsing secondary multiple sclerosis using generic cladribine. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22, 593-594.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25224
Petrova N, Carassiti D, Scaravilli F, Baker D, Schmierer K (2016). Synaptic loss in the MS spinal cord: a key driver of disease progression?. MULTIPLE SCLEROSIS JOURNAL. Conference: ECTRIMS 2016 Committees (UCL Institute of Neurology, London, UK) from: 14/09/2016 to: 17/09/2016, vol. 22, 80-80.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25227
Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Espasandin M, Turner BP, Gnanapavan S, Marta M, Giovannoni G et al. (2016). Treating multiple sclerosis with generic cladribine. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) vol. 22, 604-605.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25052
Sevastou I, Pryce G, Baker D, Selwood DL(2016). Characterisation of Transcriptional Changes in the Spinal Cord of the Progressive Experimental Autoimmune Encephalomyelitis Biozzi ABH Mouse Model by RNA Sequencing. PLOS ONE vol. 11, (6) e0157754-e0157754.
10.1371/journal.pone.0157754
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13513
Ummenthum K, Peferoen LAN, Finardi A, Baker D, Pryce G, Mantovani A, Bsibsi M, Bottazzi B et al.(2016). Pentraxin-3 is upregulated in the central nervous system during MS and EAE, but does not modulate experimental neurological disease. Eur J Immunol vol. 46, (3) 701-711.
10.1002/eji.201545950
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13679
Warne J, Pryce G, Hill JM, Shi X, Lennerås F, Puentes F, Kip M, Hilditch L et al.(2016). Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis. J Biol Chem vol. 291, (9) 4356-4373.
10.1074/jbc.M115.700385
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11312
Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D(2015). Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids. Journal of Neuroimmune Pharmacology vol. 10, (2) 281-292.
10.1007/s11481-014-9575-8
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11925
Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D et al.(2015). No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm vol. 2, (6)
10.1212/NXI.0000000000000158
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12681
Ruz Maldonado I, Pingitore A, Liu B, Huang GC, Baker D, Bermudez-Silva FJ, Persaud SJ (2015). Stimulation of insulin secretion by cannabinoid ligands LH-21 and Abn-CBD in mouse and human islets: evaluation of the role of GPR55. DIABETOLOGIA. vol. 58, S86-S86.
Pryce G, Baker D(2015). Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis. Evid Based Med vol. 20, (4)
10.1136/ebmed-2015-110198
Vainchtein I, Vinet J, Al-Izki S, Pryce G, Grit C, Brouwer N, Amor S, Baker D et al. (2015). Microglia are involved in apoptotic clearance during chronic-relapsing EAE. GLIA. vol. 63, E353-E353.
Ramaglia V, Jackson SJ, Hughes TR, Neal JW, Baker D, Morgan BP(2015). Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Clinical and Experimental Immunology vol. 180, (3) 432-441.
10.1111/cei.12595
Ramaglia V, Jackson SJ, Hughes TR, Neal JW, Baker D, Morgan BP(2015). Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Clin Exp Immunol vol. 180, (3) 432-441.
10.1111/cei.12595
Wu D, Cerutti C, Lopez-Ramirez MA, Pryce G, King-Robson J, Simpson JE, van der Pol SM, Hirst MC et al.(2015). Brain endothelial miR-146a negatively modulates T-cell adhesion through repressing multiple targets to inhibit NF-κB activation. J Cereb Blood Flow Metab vol. 35, (3) 412-423.
10.1038/jcbfm.2014.207
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9649
Biela A, Watkinson M, Meier UC, Baker D, Giovannoni G, Becer CR, Krause S(2015). Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy. Biosensors and Bioelectronics vol. 68, 660-667.
10.1016/j.bios.2015.01.060
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9710
Wu D, Cerutti C, Lopez-Ramirez MA, Pryce G, King-Robson J, Simpson JE, Van Der Pol SMA, Hirst MC et al.(2015). Brain endothelial miR-146a negatively modulates T-cell adhesion through repressing multiple targets to inhibit NF-κB activation. Journal of Perinatology vol. 35, (3) 412-423.
10.1038/jcbfm.2014.207
Pryce G, Baker D(2015). Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis. Handb Exp Pharmacol vol. 231, 213-231.
10.1007/978-3-319-20825-1_7
Baker D, Amor S(2015). Mouse models of multiple sclerosis: lost in translation?. Curr Pharm Des vol. 21, (18) 2440-2452.
10.2174/1381612821666150316122706
Giovannoni G, Baker D, Schmierer K(2015). The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?. Mult Scler Relat Disord vol. 4, (1) 3-5.
10.1016/j.msard.2014.11.005
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11979
Von Kutzleben S, Pryce G, Chretien N, Turner M, Siders W, Baker D (2014). Inhibition of relapsing experimental autoimmune encephalomyelitis in Biozzi ABH mice using a mouse CD52-specific monoclonal antibody. JOURNAL OF NEUROIMMUNOLOGY. vol. 275, 228-228.
10.1016/j.jneuroim.2014.08.611
Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner B, Calado-Marta M, Juliusson G, Baker D et al. (2014). CANCER RISK IN MULTIPLE SCLEROSIS PATIENTS TAKING CLADRIBINE. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 85,
10.1136/jnnp-2014-309236.140
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7246
Giovannoni G, Baker D, Schmierer K(2014). Simvastatin in patients with progressive multiple sclerosis. Lancet vol. 384, (9947)
10.1016/S0140-6736(14)61621-4
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11982
Pakpoor J, Nyein S, Disanto G, Nwosu A, Baker D, Giovannoni G (2014). A global analysis of the use of social media to discuss multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 334-335.
Liu B, Song S, Baker D, Hassan Z, Drynda RL, Bowe JE, Jones PM, Persaud SJ(2014). Knockout of GPR55 impairs insulin secretion and reduces islet cell turnover. DIABETOLOGIA vol. 57, S49-S49.
Amor S, van der Star BJ, Bosca I, Raffel J, Gnanapavan S, Watchorn J, Kuhle J, Giovannoni G et al.(2014). Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis. Mult Scler vol. 20, (10) 1355-1362.
10.1177/1352458514521887
Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE, Reijerkerk A, King-Robson J, Kay O, de Vries HE et al.(2014). MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation. FASEB J vol. 28, (6) 2551-2565.
10.1096/fj.13-248880
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7990
Browne L, Lidster K, Al-Izki S, Clutterbuck L, Posada C, Chan AWE, Riddall D, Garthwaite J et al.(2014). Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis. J Med Chem vol. 57, (7) 2942-2952.
10.1021/jm401881q
Liu B, Song S, Baker D, Hassan Z, Drynda RL, Bowe JE, Jones PM, Persaud SJ(2014). GPR55 deletion is coupled to impaired insulin secretion and reduced islet cell turnover. DIABETIC MEDICINE vol. 31, 9-9.
Puentes F, Topping J, Kuhle J, van der Star BJ, Douiri A, Giovannoni G, Baker D, Amor S et al.(2014). Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry vol. 85, (3) 274-278.
10.1136/jnnp-2013-305494
Song S, Liu B, Bowe JE, Baker D, Jones PM, Persaud SJ(2014). Specificity of GPR55 agonists and antagonist in the regulation of calcium handling and insulin secretion by mouse islets. DIABETIC MEDICINE vol. 31, 32-32.
Van Den Elsen PJ, Van Eggermond MCJA, Puentes F, Van Der Valk P, Baker D, Amor S(2014). The epigenetics of multiple sclerosis and other related disorders. Multiple Sclerosis and Related Disorders vol. 3, (2) 163-175.
10.1016/j.msard.2013.08.007
Whyte L, Khalid A, Finnie G, Chiu S, Baker D, Aspden R, Ross R (2014). GPR55 Regulates Peak Bone Mass and Steroid Hormone Levels in Male Mice. JOURNAL OF BONE AND MINERAL RESEARCH. vol. 29, S409-S409.
Pryce G, Visintin C, Ramagopalan SV, Al-Izki S, De Faveri LE, Nuamah RA, Mein CA, Montpetit A et al.(2014). Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists. FASEB J vol. 28, (1) 117-130.
10.1096/fj.13-239442
Baker D, Amor S(2014). Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely. Multiple Sclerosis and Related Disorders
10.1016/j.msard.2014.05.002
Amor S, Peferoen LAN, Vogel DYS, Breur M, van der Valk P, Baker D, Van Noort JM(2014). Inflammation in neurodegenerative diseases - an update. Immunology vol. 142, (2) 151-166.
10.1111/imm.12233
Mullen L, Rigby A, Sclanders M, Adams G, Mittal G, Colston J, Fatah R, Subang C et al.(2014). Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β. Expert Opin Drug Deliv vol. 11, (1) 5-16.
10.1517/17425247.2013.839655
Mullen L, Adams G, Layward L, Vessillier S, Annenkov A, Mittal G, Rigby A, Sclanders M et al.(2014). Latent cytokines for targeted therapy of inflammatory disorders. Expert Opin Drug Deliv vol. 11, (1) 101-110.
10.1517/17425247.2014.863872
Al-Izki S, Pryce G, Hankey DJR, Lidster K, von Kutzleben SM, Browne L, Clutterbuck L, Posada C et al.(2014). Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis. Brain vol. 137, (Pt 1) 92-108.
10.1093/brain/awt324
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9650
Baker D, Pepper G, Yauner F, Giovannoni G(2014). MSer - A new, neutral descriptor for someone with multiple sclerosis. Multiple Sclerosis and Related Disorders vol. 3, (1) 31-33.
10.1016/j.msard.2013.06.010
Baker D, Lidster K, Sottomayor A, Amor S(2014). Two years later: journals are not yet enforcing the ARRIVE guidelines on reporting standards for pre-clinical animal studies. PLoS Biol vol. 12, (1)
10.1371/journal.pbio.1001756
https://qmro.qmul.ac.uk/xmlui/handle/123456789/10590
Hampton DW, Serio A, Pryce G, Al-Izki S, Franklin RJ, Giovannoni G, Baker D, Chandran S(2013). Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. Acta Neuropathol Commun vol. 1,
10.1186/2051-5960-1-84
https://qmro.qmul.ac.uk/xmlui/handle/123456789/18967
Pryce G, Cabranes A, Fernández-Ruiz J, Bisogno T, Di Marzo V, Long JZ, Cravatt BF, Giovannoni G et al.(2013). Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors. Mult Scler vol. 19, (14) 1896-1904.
10.1177/1352458513485982
Delarasse C, Smith P, Baker D, Amor S(2013). Novel pathogenic epitopes of myelin oligodendrocyte glycoprotein induce experimental autoimmune encephalomyelitis in C57BL/6 mice. Immunology vol. 140, (4) 456-464.
10.1111/imm.12155
James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV(2013). The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Mult Scler vol. 19, (12) 1571-1579.
10.1177/1352458513489756
Puentes F, van der Star BJ, Victor M, Kipp M, Beyer C, Peferoen-Baert R, Ummenthum K, Pryce G et al.(2013). Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis. Journal of Neuroinflammation vol. 10,
10.1186/1742-2094-10-118
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7824
Liu B, Song S, Baker D, Bowe J, Hassan Z, Drynda R, Jones P, Persaud S (2013). GPR55 deletion is coupled to impaired glucose tolerance and increased islet cell apoptosis. DIABETOLOGIA. vol. 56, S46-S46.
Di Filippo M, Chiasserini D, Gardoni F, Viviani B, Tozzi A, Giampa C, Costa C, Tantucci M et al.(2013). Effects of central and peripheral inflammation on hippocampal synaptic plasticity. NEUROBIOLOGY OF DISEASE vol. 52, 229-236.
10.1016/j.nbd.2012.12.009
Baker D, Lidster K, Al-Izki S, Pryce G, Giovannoni G(2013). Animal models of progressive disability in MS. IRISH JOURNAL OF MEDICAL SCIENCE vol. 182, S5-S6.
Sisay S, Pryce G, Jackson SJ, Tanner C, Ross RA, Michael GJ, Selwood DL, Giovannoni G et al.(2013). Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis. PLoS One vol. 8, (10)
10.1371/journal.pone.0076907
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6281
Baker D, Pepper G, Yauner F, Giovannoni G(2013). MSer - A new, neutral descriptor for someone with multiple sclerosis. Multiple Sclerosis and Related Disorders
10.1016/j.msard.2013.06.010
Lidster K, Jackson SJ, Ahmed Z, Munro P, Coffey P, Giovannoni G, Baker MD, Baker D(2013). Neuroprotection in a novel mouse model of multiple sclerosis. PLoS One vol. 8, (11)
10.1371/journal.pone.0079188
https://qmro.qmul.ac.uk/xmlui/handle/123456789/10591
van den Elsen PJ, van Eggermond MCJA, Puentes F, van der Valk P, Baker D, Amor S(2013). The epigenetics of multiple sclerosis and other related disorders. Multiple Sclerosis and Related Disorders
10.1016/j.msard.2013.08.007
Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE, Reijerkerk A, King-Robson J, de Vries HE, Hirst MC et al. (2012). Endothelial miR-155 promotes blood brain barrier dysfunction in neuroinflammation. JOURNAL OF NEUROIMMUNOLOGY. vol. 253, 3-4.
van der Star B, Puentes F, Gerritsen W, Huizinga R, Reijerkerk A, van der Valk P, Baker D, Amor S (2012). Neuronal specific T cells are pathogenic in Biozzi mice - Implications for MS. JOURNAL OF NEUROIMMUNOLOGY. vol. 253, 155-155.
Baker D, Lidster K, Sottomayor A, Amor S(2012). Reproducibility: Research-reporting standards fall short. Nature vol. 492, (7427)
10.1038/492041a
Baker D, Lidster K, Sottomayor A, Amor S(2012). Reproducibility: Research-reporting standards fall short. Nature vol. 492, (7427)
10.1038/492041a
Fox RJ, Thompson A, Baker D, Baneke P, Brown D, Browne P, Chandraratna D, Ciccarelli O et al.(2012). Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS. MULTIPLE SCLEROSIS JOURNAL vol. 18, (11) 1534-1540.
10.1177/1352458512458169
https://qmro.qmul.ac.uk/xmlui/handle/123456789/10916
Song S, Liu B, Baker D, Huang GC, Amiel SA, King AJ, Bowe JE, Jones PM et al.(2012). Islet GPR55 is coupled to increased insulin secretion and decreased apoptosis. DIABETOLOGIA vol. 55, S163-S163.
Li C, Bowe JE, Baker D, Jones PM, Persaud SJ(2012). PS 014 Beta cell GPCRs and other signalling mechanisms. DIABETOLOGIA vol. 55, S163-S163.
van der Star BJ, Vogel DYS, Kipp M, Puentes F, Baker D, Amor S(2012). In Vitro and In Vivo Models of Multiple Sclerosis. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS vol. 11, (5) 570-588.
10.2174/187152712801661284
van Noort JM, Baker D, Amor S(2012). Mechanisms in the Development of Multiple Sclerosis Lesions: Reconciling Autoimmune and Neurodegenerative Factors. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS vol. 11, (5) 556-569.
10.2174/187152712801661293
Baker D, Amor S(2012). Multiple sclerosis - from bench to bedside. CNS Neurol Disord Drug Targets vol. 11, (5) 495-496.
10.2174/187152712801661211
Lidster K, Baker D(2012). Optical coherence tomography detection of neurodegeneration in multiple sclerosis. CNS Neurol Disord Drug Targets vol. 11, (5) 518-527.
10.2174/187152712801661185
Pryce G, Baker D(2012). Potential control of multiple sclerosis by cannabis and the endocannabinoid system. CNS Neurol Disord Drug Targets vol. 11, (5) 624-641.
10.2174/187152712801661310
Amor S, Baker D(2012). Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders. Multiple Sclerosis and Related Disorders vol. 1, (3) 111-115.
10.1016/j.msard.2012.01.003
Gnanapavan S, Grant D, Pryce G, Jackson S, Baker D, Giovannoni G(2012). Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis. Autoimmunity vol. 45, (4) 298-303.
10.3109/08916934.2012.654865
Baker D, Pryce G, Jackson SJ, Bolton C, Giovannoni G(2012). The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Multiple Sclerosis and Related Disorders vol. 1, (2) 64-75.
10.1016/j.msard.2011.11.001
Baker D, Amor S(2012). Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis. J Neuroimmunol vol. 242, (1-2) 78-83.
10.1016/j.jneuroim.2011.11.003
Kipp M, Van Der Star B, Vogel DYS, Puentes F, Van Der Valk P, Baker D, Amor S(2012). Experimental in vivo and in vitro models of multiple sclerosis: EAE and beyond. Multiple Sclerosis and Related Disorders vol. 1, (1) 15-28.
10.1016/j.msard.2011.09.002
Sher F, Amor S, Gerritsen W, Baker D, Jackson SL, Boddeke E, Copray S(2012). Intraventricularly Injected Olig2-NSCs Attenuate Established Relapsing-Remitting EAE in Mice. CELL TRANSPLANTATION vol. 21, (9) 1883-1897.
10.3727/096368911X637443
Al-Izki S, Pryce G, O'Neill JK, Butter C, Giovannoni G, Amor S, Baker D(2012). Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Multiple Sclerosis and Related Disorders vol. 1, (1) 29-38.
10.1016/j.msard.2011.09.001
Puentes F, van der Star B, Huizinga R, Gerritsen W, van der Valk P, Baker D, Amor S(2011). Autoimmunity to axonal proteins in multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL vol. 17, S329-S329.
Jackson S, Giovannoni G, Baker D(2011). Fingolimod (FTY720) modulates microglial activation to augment markers of remyelination. MULTIPLE SCLEROSIS JOURNAL vol. 17, S210-S210.
Lidster K, Jackson S, Coffey P, Baker M, Garthwaite J, Selwood D, Giovannoni G, Baker D(2011). Neuroprotection in a novel optic neuritis model. MULTIPLE SCLEROSIS JOURNAL vol. 17, S435-S435.
Al-Izki S, Pryce G, Amor S, Gerritsen W, Garthwaite J, Giovannoni G, Selwood DL, Baker D(2011). Selective targeting of neuroprotection to MS lesions: sodium channel blockers in experimental autoimmune encephalomyelitis. MULTIPLE SCLEROSIS JOURNAL vol. 17, S209-S210.
Pryce G, Visintin C, Lutz B, Marsicano G, Giovannoni G, Selwood DL, Baker D(2011). Selective targeting of spasticity by CNS-excluded cannabinoids. MULTIPLE SCLEROSIS JOURNAL vol. 17, S247-S247.
Baker D, Pryce G, Visintin C, Pertwee RG, Tanner C, Ross R, Irving A, Sisay S et al.(2011). VSN16R a novel agent for the control of spasticity. MULTIPLE SCLEROSIS JOURNAL vol. 17, S243-S243.
Ayoub SS, Pryce G, Seed MP, Bolton C, Flower RJ, Baker D(2011). Paracetamol-induced hypothermia is independent of cannabinoids and transient receptor potential vanilloid-1 and is not mediated by AM404. Drug Metab Dispos vol. 39, (9) 1689-1695.
10.1124/dmd.111.038638
Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D(2011). Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Mult Scler vol. 17, (8) 939-948.
10.1177/1352458511400476
Jackson SJ, Giovannoni G, Baker D(2011). Fingolimod modulates microglial activation to augment markers of remyelination. J Neuroinflammation vol. 8,
10.1186/1742-2094-8-76
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7825
Baker D, Gerritsen W, Rundle J, Amor S(2011). Critical appraisal of animal models of multiple sclerosis. Mult Scler vol. 17, (6) 647-657.
10.1177/1352458511398885
Baker D, Amor S(2010). Editorial: Quality control of experimental autoimmune encephalomyelitis. Multiple Sclerosis vol. 16, (9) 1025-1027.
10.1177/1352458510378317
Baker D, Amor S(2010). Quality control of experimental autoimmune encephalomyelitis. Mult Scler vol. 16, (9) 1025-1027.
10.1177/1352458510378317
Amor S, Puentes F, Baker D, van der Valk P(2010). Inflammation in neurodegenerative diseases. IMMUNOLOGY vol. 129, (2) 154-169.
10.1111/j.1365-2567.2009.03225.x
Idris AI, Sophocleous A, Landao-Bassonga E, Canals M, Milligan G, Baker D, van't Hof RJ, Ralston SH(2009). Cannabinoid Receptor Type 1 Protects against Age-Related Osteoporosis by Regulating Osteoblast and Adipocyte Differentiation in Marrow Stromal Cells. CELL METAB vol. 10, (2) 139-147.
10.1016/j.cmet.2009.07.006
Al-Izki S, Pryce G, Giovannoni G, Baker D(2009). Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography. Mult Scler vol. 15, (7) 795-801.
10.1177/1352458509104594
Idris AI, Sophocleous A, Landao-Bassonga E, Merkouris M, Milligan GI, Baker D, van't Hof RJ, Ralston SH (2009). Cannabinoid receptor type 1 protects against age-related bone loss by regulating osteoblast and adipocyte differentiation of bone marrow stromal cells. BONE. vol. 44, S222-S222.
10.1016/j.bone.2009.03.067
Hooper C, Pinteaux-Jones F, Fry VA, Sevastou IG, BAKER D, Heales SJ, Pocock JM(2009). Differential effects of albumin on microglia and macrophages; implications for neurodegeneration following blood-brain barrier damage. J Neurochem vol. 109, (3) 694-705.
10.1111/j.1471-4159.2009.05953.x
Amor S, Baker D(2009). Experimental autoimmune encephalomyelitis. The Biology of Multiple Sclerosis,
Rigby A, Baker D, Chernajovsky Y (2008). Targeting EPO to the CNS; development of a novel therapeutic strategy. IMMUNOLOGY. vol. 125, 134-135.
Hampton DW, Anderson J, Pryce G, Irvine KA, Giovannoni G, Fawcett JW, Compston A, Franklin RJM et al.(2008). An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J NEUROIMMUNOL vol. 201, 200-211.
10.1016/j.jneuroim.2008.05.034
Jackson S, Al-Izik S, Pryce G, Giovannoni G, Baker D (2008). Fingolimod reduces axonal loss in relapsing secondary progressive experimental autoimmune encephalomyelitis. MULTIPLE SCLEROSIS. vol. 14, S80-S81.
Parkes H, Shorter S, So PW, Baker D, Pryce G, Giovannoni G, Schmierer K (2008). High resolution 1H nuclear magnetic resonance spectroscopic-based metabolomic urine analysis of experimental autoimmune encephalitis, a model disease of multiple sclerosis. MULTIPLE SCLEROSIS. vol. 14, S86-S87.
Al-Izki S, Pryce G, Jackson S, Giovannoni G, Baker D (2008). Neuroprotective effects of omega-3 fatty acids in a mouse model of multiple sclerosis. JOURNAL OF NEUROIMMUNOLOGY. vol. 197, 173-173.
Rigby A, Chernajovsky Y, Baker D (2008). Targeting EPO to the CNS; Development of a novel therapeutic strategy. JOURNAL OF NEUROIMMUNOLOGY. vol. 197, 171-171.
Anderson JM, Hampton DW, Patani R, Pryce G, Crowther RA, Reynolds R, Franklin RJM, Giovannoni G et al.(2008). Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. BRAIN vol. 131, 1736-1748.
10.1093/brain/awn119
Pinteaux-Jones F, Sevastou IG, Fry VAH, Heales S, Baker D, Pocock JM(2008). Myelin-induced microglial neurotoxicity can be controlled by microglial metabotropic glutamate receptors. J NEUROCHEM vol. 106, (1) 442-454.
10.1111/j.1471-4159.2008.05426.x
East E, Gveri¿ D, Baker D, Pryce G, Lijnen HR, Cuzner ML(2008). Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation. Neuropathol Appl Neurobiol vol. 34, (2) 216-230.
10.1111/j.1365-2990.2007.00889.x
Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, Yamamura T, Baker D(2008). Cannabinoid-mediated neuroprotection, not immuno suppression, may be more relevant to multiple sclerosis. J NEUROIMMUNOL vol. 193, (1-2) 120-129.
10.1016/j.jneuroim.2007.10.024
Pryce G, Jackson SJ, Baker D(2008). Cannabinoids for the control of multiple sclerosis. Cannabinoids and the Brain,
Baker D, Pryce G(2008). The endocannabinoid system and multiple sclerosis. Curr Pharm Des vol. 14, (23) 2326-2336.
10.2174/138161208785740036
Baker D, Jackson SJ, Pryce G(2007). Cannabinoid control of neuroinflammation related to multiple sclerosis. BRIT J PHARMACOL vol. 152, (5) 649-654.
10.1038/sj.bjp.0707458
Hoi PM, Visintin C, Okuyama M, Gardiner SM, Kaup SS, Bennett T, Baker D, Selwood DL et al.(2007). Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl) benzamide (VSN16) in the rat. BRIT J PHARMACOL vol. 152, (5) 751-764.
10.1038/sj.bjp.0707470
Pocock JM, Pinteaux-Jones F, Fry VA, Baker D, Heales SJ (2007). Metabotropic glutamate receptors on microglia: Switching off toxicity. JOURNAL OF NEUROCHEMISTRY. vol. 102, 239-239.
Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng XD et al.(2007). Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. NAT MED vol. 13, (4) 492-497.
10.1038/nm1561
Pryce G, Baker D(2007). Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. BRIT J PHARMACOL vol. 150, (4) 519-525.
10.1038/sj.bjp.0707003
Baker D, Croxford JL, Pryce G, Jackson SM, Ledent C, Marsicano G, Lutz B, Giovannoni G et al. (2006). Cannabinoid-mediated immunosuppression in experimental allergic encephalomyelitis. JOURNAL OF NEUROIMMUNOLOGY. vol. 178, 90-91.
Baker D (2006). Protection of axonal damage in experimental antoimmune encephalomyelitis. MULTIPLE SCLEROSIS. vol. 12, S12-S13.
Baker D (2006). Role of immunity in neurodegeneration in autoimmune encephalomyelitis. JOURNAL OF NEUROIMMUNOLOGY. vol. 178, 20-20.
Cabranes A, Pryce G, Baker D, Fernandez-Ruiz J(2006). Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. BRAIN RES vol. 1107, 199-205.
10.1016/j.brainres.2006.06.001
Bilsland LG, Dick JRT, Pryce G, Petrosino S, Di Marzo V, Baker D, Greensmith L(2006). Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J vol. 20, (7) 1003-+.
10.1096/fj.05-4743fje
Baker D, Pryce G, Croxford JL, Yamamura T (2006). Cannabinoid-mediated immunosuppression in experimental allergic encephalomyelitits. CURRENT TOPICS IN NEUROIMMUNOLOGY. Editors: Tabira, T, Yamamura, T, Kira, J, 109-116.
Cristino L, De Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V(2006). Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. NEUROSCIENCE vol. 139, (4) 1405-1415.
10.1016/j.neuroscience.2006.02.074
Baker D, Pryce G, Davies WL, Hiley CR(2006). In silico patent searching reveals a new cannabinoid receptor. TRENDS PHARMACOL SCI vol. 27, (1) 1-4.
10.1016/j.tips.2005.11.003
Ligresti A, Cascio MG, Pryce G, Kulasegram S, Beletskaya I, De Petrocellis L, Saha B, Mahadevan A et al.(2006). New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. BRIT J PHARMACOL vol. 147, (1) 83-91.
10.1038/sj.bjp.0706418
de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Cabranes A, Pryce G, Baker D, Lopez-Rodriguez M, Ramos JA(2006). UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. EUR NEUROPSYCHOPHARM vol. 16, (1) 7-18.
10.1016/j.euroneuro.2005.06.001
Heijmans N, Smith PA, Morris-Downes MM, Pryce G, Baker D, Donaldson AVJ, 't Hart B, Amor S(2005). Encephalitogenic and tolerogenic potential of altered peptide ligands of MOG and PLP in Biozzi ABH mice. J NEUROIMMUNOL vol. 167, (1-2) 23-33.
10.1016/j.jneuroim.2005.06.005
East E, Baker D, Pryce G, Lijnen HR, Cuzner ML, Gveri¿ D(2005). A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am J Pathol vol. 167, (2) 545-554.
10.1016/S0002-9440(10)62996-3
Pryce G, O'Neill JK, Croxford JL, Amor S, Hankey DJ, East E, Giovannoni G, Baker D(2005). Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. J NEUROIMMUNOL vol. 165, (1-2) 41-52.
10.1016/j.jneuroim.2005.04.009
Amor S, Smith PA, 't Hart B, Baker D(2005). Biozzi mice: Of mice and human neurological diseases. J NEUROIMMUNOL vol. 165, (1-2) 1-10.
10.1016/j.jneuroim.2005.04.010
Smith PA, Morris-Downes M, Heijmans N, Pryce G, Arter E, O'Neill JK, 't Hart B, Baker D et al.(2005). Epitope spread is not critical for the relapse and progression of MOG 8-21 induced EAE in Biozzi ABH mice. J NEUROIMMUNOL vol. 164, (1-2) 76-84.
10.1016/j.jneuroim.2005.04.006
Idris AI, Hof RJV, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH(2005). Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. NAT MED vol. 11, (7) 774-779.
10.1038/nm1255
Jackson SJ, Diemel LT, Pryce G, Baker D (2005). Cannabinoids and neuroprotection in CNS inflammatory disease. JOURNAL OF THE NEUROLOGICAL SCIENCES. vol. 233, 21-25.
10.1016/j.jns.2005.03.002
Idris AI, Van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH (2005). Cannabinoid receptor 1 knockout mice have increased bone mass and are protected from ovariectomy-induced bone loss. BONE. vol. 36, S132-S132.
Pryce G, Baker D(2005). Emerging properties of cannabinoid medicines in management of multiple sclerosis. TRENDS NEUROSCI vol. 28, (5) 272-276.
10.1016/j.tins.2005.03.006
Visintin C, Aliev AE, Riddall D, Baker D, Okuyama M, Hoi PM, Hiley R, Selwood DL(2005). Membrane receptor probes: Solid-phase synthesis of biotin-Asp-PEG-arvanil derivatives. ORG LETT vol. 7, (9) 1699-1702.
10.1021/ol0502578
Gegg ME, Harry R, Hankey D, Zambarakji H, Pryce G, Baker D, Adamson P, Calder V et al.(2005). Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. J IMMUNOL vol. 174, (4) 2327-2335.
10.4049/jimmunol.174.4.2327
Jackson SJ, Pryce G, Diemel LT, Cuzner ML, Baker D(2005). Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. NEUROSCIENCE vol. 134, (1) 261-268.
10.1016/j.neuroscience.2005.02.045
Constantinescu CS, Baker D(2005). Cytokines in experimental autoimmune encephalomyelitis. Experimental Models of Multiple Sclerosis,
Baker D(2005). Genetics of experimental allergic encephalomyelitis. Experimental Models of Multiple Sclerosis,
Jackson SJ, Baker D, Cuzner ML, Diemel LT(2004). Cannabinoid-mediated neuroprotection following interferon-gamma treatment in a three-dimensional mouse brain aggregate cell culture. EUR J NEUROSCI vol. 20, (9) 2267-2275.
10.1111/j.1460-9568.2004.03711.x
Idris AI, Van't Hof' RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH (2004). Regulation of osteoclastic bone resorption and bone mass by the cannabinoid receptor 1 pathway. JOURNAL OF BONE AND MINERAL RESEARCH. vol. 19, S284-S284.
Pryce G, Jackson SM, Hankey DRJ, Giovannoni G, Baker D (2004). Cannabinoids are neuroprotective: dissociation of true neuroprotection from protection secondary to immunosuppression. JOURNAL OF NEUROIMMUNOLOGY. vol. 154, 78-78.
Heijmans N, Smith P, Pryce D, Baker D, Morris-Downes M, Amor S (2004). Non-encephalitogenic single amino acid substitutions of MOG 8-21 and PLP 56-70 suppress relapsing EAE in ABH mice. JOURNAL OF NEUROIMMUNOLOGY. vol. 154, 60-60.
Baker D, Pryce G(2004). The potential role of the endocannabinoid system in the control of multiple scleorsis. Current Medicinal Chemistry - Central Nervous System Agents vol. 4, (3) 195-202.
10.2174/1568015043356977
East E, Baker D, Pryce G, Cuzner ML, Gveric D (2004). The role of plasminogen activators in experimental allergic encephalomyelitis: inflammation and axonal pathology. JOURNAL OF NEUROIMMUNOLOGY. vol. 154, 167-167.
Ellmerich S, Takacs K, Mycko M, Waldner H, Wahid F, Boyton RJ, Smith PA, Amor S et al.(2004). Disease-related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis. EUR J IMMUNOL vol. 34, (7) 1839-1848.
10.1002/eji.200324044
de Lago E, Ligresti A, Ortar G, Morera E, Cabranes A, Pryce G, Bifulco M, Baker D et al.(2004). In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. EUR J PHARMACOL vol. 484, (2-3) 249-257.
10.1016/j.ejphar.2003.11.027
Wilkinson JD, Whalley BJ, Baker D, Pryce G, Constanti A, Gibbons S, Williamson EM(2003). Medicinal cannabis: is Delta(9)-tetrahydrocannabinol necessary for all its effects?. J PHARM PHARMACOL vol. 55, (12) 1687-1694.
10.1211/0022357022304
Pryce G, Ahmed Z, Hankey DJR, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A et al.(2003). Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. BRAIN vol. 126, 2191-2202.
10.1093/brain/awg224
Craner MJ, Kataoka Y, Lo AC, Black JA, Baker D, Waxman SG(2003). Temporal course of upregulation of Na-v 1.8 in Purkinje neurons parallels the progression of clinical deficit in experimental allergic encephalomyelitis. J NEUROPATH EXP NEUR vol. 62, (9) 968-975.
10.1093/jnen/62.9.968
East E, Baker D, Pryce GM, Cuzner ML, Gveric D (2003). The role of plasminogen activators in experimental allergic encephalomyelitis. GLIA. 40-40.
Ahmed Z, Baker D, Cuzner ML(2003). Interleukin-12 induces mild experimental allergic encephalomyelitis following local central nervous system injury in the Lewis rat. J NEUROIMMUNOL vol. 140, (1-2) 109-117.
10.1016/S0165-5728(03)00180-2
Giovannoni G, Baker D(2003). Inflammatory disorders of the central nervous system. CURR OPIN NEUROL vol. 16, (3) 347-350.
10.1097/01.wco.0000073936.19076.9c
Hall RJ, Hollis-Moffatt JE, Merriman ME, Green RA, Baker D, Merriman TR(2003). An autoimmune diabetes locus (Idd21) on mouse Chromosome 18. MAMM GENOME vol. 14, (5) 335-339.
10.1007/s00335-002-3064-8
Baker D, Hankey DJR(2003). Gene therapy in autoimmune, demyelinating disease of the central nervous system. GENE THER vol. 10, (10) 844-853.
10.1038/sj.gt.3302025
Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, Adamson P(2003). Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J vol. 17, (8) 905-907.
10.1096/fj.02-1014fje
Pryce G, Giovannoni G, Baker D(2003). Mifepristone or inhibition of 11 beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in mice. NEUROSCI LETT vol. 341, (2) 164-166.
10.1016/S0304-3940(03)00159-9
Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, Giovannoni G(2003). Quantification of neurodegeneration by measurement of brain-specific proteins. J NEUROIMMUNOL vol. 138, (1-2) 45-48.
10.1016/S0165-5728(03)00092-4
Baker D, Pryce G, Giovannoni G, Thompson AJ(2003). The therapeutic potential of cannabis. LANCET NEUROL vol. 2, (5) 291-298.
10.1016/S1474-4422(03)00381-8
Baker D, Pryce G(2003). The therapeutic potential of cannabis in multiple sclerosis. EXPERT OPIN INV DRUG vol. 12, (4) 561-567.
10.1517/13543784.12.4.561
Craner MJ, Lo AC, Black JA, Baker D, Newcombe J, Cuzner ML, Waxman SG(2003). Annexin II/piII is up-regulated in Purkinje cells in EAE and MS. NEUROREPORT vol. 14, (4) 555-558.
10.1097/01.wnr.0000061018.47393.38
Baker D, Adamson P, Greenwood J(2003). Potential of statins for the treatment of multiple sclerosis. LANCET NEUROL vol. 2, (1) 9-10.
10.1016/S1474-4422(03)00256-4
Ahmed Z, Doward AI, Pryce G, Taylor DL, Pocock JM, Leonard JP, Baker D, Cuzner ML(2002). A role for caspase-1 and-3 in the pathology of experimental allergic encephalomyelitis - Inflammation versus degeneration. AM J PATHOL vol. 161, (5) 1577-1586.
10.1016/S0002-9440(10)64436-7
Hall RJ, Hollis-Moffat JE, Merriman ME, Bridges RJ, Green RA, Williams G, Baker D, Merriman TR (2002). An autoimmune diabetes locus (ldd21) on mouse chromosome 18. AMERICAN JOURNAL OF HUMAN GENETICS. vol. 71, 446-446.
Thompson AJ, Baker D(2002). Cannabinoids in MS - Potentially useful but not just yet!. NEUROLOGY vol. 58, (9) 1323-1324.
10.1212/wnl.58.9.1323
Walters CE, Pryce G, Hankey DJR, Sebti SM, Hamilton AD, Baker D, Greenwood J, Adamson P(2002). Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. J IMMUNOL vol. 168, (8) 4087-4094.
10.4049/jimmunol.168.8.4087
Morris-Downes MM, Smith PA, Rundle JL, Piddlesden SJ, Baker D, Pham-Dinh D, Heijmans N, Amor S(2002). Pathological and regulatory effects of anti-myelin antibodies in experimental allergic encephalomyelitis in mice. J NEUROIMMUNOL vol. 125, (1-2) 114-124.
10.1016/S0165-5728(02)00040-1
Youssef F, Seifalian AM, Jagroop IA, Myint F, Baker D, Mikhailidis DP, Hamilton G(2002). The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT)dagger. EUR J VASC ENDOVASC vol. 23, (4) 358-364.
10.1053/ejvs.2002.1611
Brooks JW, Pryce G, Bisogno T, Jaggar SI, Hankey DJR, Brown P, Bridges D, Ledent C et al.(2002). Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors. EUR J PHARMACOL vol. 439, (1-3) 83-92.
10.1016/s0014-2999(02)01369-9
Morris-Downes MM, McCormack K, Baker D, Sivaprasad D, Natkunarajah J, Amor S(2002). Encephalitogenic and immunogenic potential of myelin-associated glycoprotein (MAG), oligodendrocyte-specific glycoprotein (OSP) and 2 ',3 '-cyclic nucleotide 3 '-phosphodiesterase (CNPase) in ABH and SJL mice. J NEUROIMMUNOL vol. 122, (1-2) 20-33.
10.1016/S0165-5728(01)00460-X
Hankey DJR, Nickerson JM, Donoso LA, Lightman SL, Baker D(2001). Experimental autoimmune uveoretinitis in mice (Biozzi ABH and NOD) expressing the autoimmune-associated H-2A(g7) molecule: identification of a uveitogenic epitope. J NEUROIMMUNOL vol. 118, (2) 212-222.
10.1016/S0165-5728(01)00341-1
Ahmed Z, Gveric D, Pryce G, Baker D, Leonard JP, Cuzner ML, Diemel LT(2001). Myelin/axonal pathology in interleukin-12 induced serial relapses of experimental allergic encephalomyelitis in the Lewis rat. Am J Pathol vol. 158, (6) 2127-2138.
10.1016/s0002-9440(10)64684-6
Croxford JL, Feldmann M, Chernajovsky Y, Baker D(2001). Different therapeutic outcomes in experimental allergic encephalomyelitis dependant upon the mode of delivery of IL-10: A comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system. J IMMUNOL vol. 166, (6) 4124-4130.
10.4049/jimmunol.166.6.4124
Reichel MB, Bainbridge J, Baker D, Thrasher AJ, Bhattacharya SS, Ali RR(2001). An immune response after intraocular administration of an adenoviral vector containing a beta galactosidase reporter gene slows retinal degeneration in the rd mouse. BRIT J OPHTHALMOL vol. 85, (3) 341-344.
10.1136/bjo.85.3.341
Hankey DJR, Lightman SL, Baker D(2001). Interphotoreceptor retinoid binding protein peptide-induced uveitis in B10.RIII mice: Characterization of disease parameters and immunomodulation. EXP EYE RES vol. 72, (3) 341-350.
10.1006/exer.2000.0957
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L et al.(2001). Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J vol. 15, (2) 300-302.
10.1096/fj.00-0399fje
Black JA, Dib-Hajj S, Baker D, Newcombe J, Cuzner ML, Waxman SG(2000). Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America vol. 97, (21) 11598-11602.
10.1073/pnas.97.21.11598
Chernajovsky Y, Dreja H, Daly G, Annenkov A, Gould D, Adams G, Croxford JL, Baker D et al.(2000). Immuno- and genetic therapy in autoimmune diseases. Genes Immun vol. 1, (5) 295-307.
10.1038/sj.gene.6363683
Baker D(2000). Reply: a sanguine approach to cannabis. Trends Pharmacol Sci vol. 21, (6)
10.1016/S0165-6147(00)01486-3
Thoua NM, van Noort JM, Baker D, Bose A, van Sechel AC, van Stipdonk MJB, Travers PJ, Amor S(2000). Encephalitogenic and immunogenic potential of the stress protein alpha B-crystallin in Biozzi ABH (H-2A(g7)) mice. JOURNAL OF NEUROIMMUNOLOGY vol. 104, (1) 47-57.
10.1016/S0165-5728(99)00246-5
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L(2000). Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature vol. 404, (6773) 84-87.
10.1038/35003583
Croxford JL, Triantaphyllopoulos KA, Neve RM, Feldmann M, Chernajovsky Y, Baker D(2000). Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor. J Immunol vol. 164, (5) 2776-2781.
10.4049/jimmunol.164.5.2776
Chernajovsky Y, Gould D, Annenkov A, Dreja H, Daly G, Rabinovich GA, Croxford L, Baker D et al.(1999). Immunotherapy of auto-immune diseases by gene transfer. Biochem Soc Trans vol. 27, (6) 869-873.
10.1042/bst0270869
Brennan FR, O'Neill JK, Allen SJ, Butter C, Nuki G, Baker D(1999). CD44 is involved in selective leucocyte extravasation during inflammatory central nervous system disease. Immunology vol. 98, (3) 427-435.
10.1046/j.1365-2567.1999.00894.x
Croxford JL, O'Neill JK, Ali RR, Browne K, Byrnes AP, Dallman MJ, Wood MJ, Fedlmann M et al.(1998). Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis. Eur J Immunol vol. 28, (12) 3904-3916.
10.1002/(SICI)1521-4141(199812)28:12<3904::AID-IMMU3904>3.0.CO;2-5
Ali RR, Reichel MB, Byrnes AP, Stephens CJ, Thrasher AJ, Baker D, Hunt DM, Bhattacharya SS(1998). Co-injection of adenovirus expressing CTLA4-Ig prolongs adenovirally mediated lacZ reporter gene expression in the mouse retina. GENE THERAPY vol. 5, (11) 1561-1565.
10.1038/sj.gt.3300761
Croxford JL, Triantaphyllopoulos K, Podhajcer OL, Feldmann M, Baker D, Chernajovsky Y(1998). Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J Immunol vol. 160, (10) 5181-5187.
O'Neill JK, Baker D, Morris MM, Gschmeissner SE, Jenkins HG, Butt AM, Kirvell SL, Amor S(1998). Optic neuritis in chronic relapsing experimental allergic encephalomyelitis in Biozzi ABH mice: Demyelination and fast axonal transport changes in disease. JOURNAL OF NEUROIMMUNOLOGY vol. 82, (2) 210-218.
10.1016/S0165-5728(97)00203-8
Chernajovsky Y, Annenkov A, Herman C, Triantaphyllopoulos K, Gould D, Dreja H, Moyes SP, Croxford JL et al.(1998). Gene therapy for rheumatoid arthritis. Theoretical considerations. Drugs and Aging vol. 12, (1) 29-41.
10.2165/00002512-199812010-00004
Triantaphyllopoulos KA, Croxford JL, Baker D, Chernajovsky Y(1998). Cloning and expression of murine IFNβ and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis. Gene Therapy vol. 5, (2) 253-263.
10.1038/sj.gt.3300570
Reichel MB, Ali RR, Thrasher AJ, Hunt DM, Bhattacharya SS, Baker D(1998). Immune responses limit adenovirally mediated gene expression in the adult mouse eye. Gene Therapy vol. 5, (8) 1038-1046.
10.1038/sj.gt.3300691
Reichet MB, All RR, Baker D, Byrnes AP, D'Esposito F, Kanuga N, Hunt DM, Bhattacharya SS(1997). Co-injection of adenovirus expressing CTLA4-IG prolongs adenovirally-mediated lacz reporter gene expression in the mouse retina. Investigative Ophthalmology and Visual Science vol. 38, (4)
Croxford JL, O'Neill JK, Baker D(1997). Polygenic control of experimental allergic encephalomyelitis in Biozzi ABH and BALB/c mice. J Neuroimmunol vol. 74, (1-2) 205-211.
10.1016/S0165-5728(96)00219-6
Morris MM, Dyson H, Baker D, Harbige LS, Fazakerley JK, Amor S(1997). Characterization of the cellular and cytokine response in the central nervous system following Semliki Forest virus infection. Journal of Neuroimmunology vol. 74, (1-2) 185-197.
10.1016/S0165-5728(96)00786-2
Amor S, Baker D, Layward L, McCormack K, Van Noort JM(1997). Multiple sclerosis: Variants on a theme. Immunology Today vol. 18, (8) 368-371.
10.1016/S0167-5699(97)01100-6
Bolton C, O¿ Neill JK, Allen SJ, Baker D(1997). Regulation of Chronic Relapsing Experimental Allergic Encephalomyelitis by Endogenous and Exogenous Glucocorticoids. International Archives of Allergy and Immunology vol. 114, (1) 74-80.
10.1159/000237646
Brennan FR, ONeill JK, Allen SJ, Mikecz K, Glant TT, Nuki G, Baker D(1996). Anti-CD44 antibody prevents and ameriolates chronic relapsing experimental allergic encephalomyelitis (CREAE) by inhibition leukocyte migration to the CNS. ARTHRITIS AND RHEUMATISM vol. 39, (9) 625-625.
Amor S, O'Neill JK, Morris MM, Smith RM, Wraith DC, Groome N, Travers PJ, Baker D(1996). Encephalitogenic epitopes of myelin basic protein, proteolipid protein, and myelin oligodendrocyte glycoprotein for experimental allergic encephalomyelitis induction in Biozzi ABH (H-2A<sup>g7</sup>) mice share an amino acid motif. Journal of Immunology vol. 156, (8) 3000-3008.
Baker D, Rosenwasser OA, O'Neill JK, Turk JL(1995). Genetic analysis of experimental allergic encephalomyelitis in mice. Journal of Immunology vol. 155, (8) 4046-4051.
Preece NE, Amor S, Baker D, Gadian DG, O'Neill JK, Urenjak J(1994). Experimental encephalomyelitis modulates inositol and taurine in the spinal cord of Biozzi mice. Magn Reson Med vol. 32, (6) 692-697.
10.1002/mrm.1910320603
Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M(1994). Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor‐immunoglobulin fusion proteins. European Journal of Immunology vol. 24, (9) 2040-2048.
10.1002/eji.1830240916
Preece NE, Baker D, Butter C, Gadian DG, Urenjak J(1993). Experimental allergic encephalomyelitis raises betaine levels in the spinal cord of strain 13 guinea-pigs. NMR Biomed vol. 6, (3) 194-200.
10.1002/nbm.1940060305
Liu GY, Baker D, Fairchild S, Figueroa F, Quartey-Papafio R, Tone M, Healey D, Cooke A et al.(1993). Complete characterization of the expressed immune response genes in Biozzi AB/H mice: structural and functional identity between AB/H and NOD A region molecules. Immunogenetics vol. 37, (4) 296-300.
10.1007/BF00187458
O'Neill JK, Baker D, Davidson AN, Allen SJ, Butter C, Waldmann H, Turk JL(1993). Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies. Journal of Neuroimmunology vol. 45, (1-2) 1-14.
10.1016/0165-5728(93)90157-T
Allen SJ, Baker D, O¿Neill JK, Davison AN, Turk JL(1993). Isolation and characterization of cells infiltrating the spinal cord during the course of chronic relapsing experimental allergic encephalomyelitis in the biozzi ab/h mouse. Cellular Immunology vol. 146, (2) 335-350.
10.1006/cimm.1993.1031
O'Neill JK, Baker D, Turk JL(1992). Inhibition of chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse. J Neuroimmunol vol. 41, (2) 177-187.
10.1016/0165-5728(92)90068-V
O'Neill JK, Baker D, Davison AN, Maggon KK, Jaffee BD, Turk JL(1992). Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of the blood-brain barrier: elucidation by the action of Brequinar sodium. J Neuroimmunol vol. 38, (1-2) 53-62.
10.1016/0165-5728(92)90090-8
Butter C, O'Neill JK, Baker D, Gschmeissner SE, Turk JL(1991). An immunoelectron microscopical study of the expression of class II major histocompatibility complex during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice. J Neuroimmunol vol. 33, (1) 37-42.
10.1016/0165-5728(91)90032-3
Butter C, Baker D, O'Neill JK, Turk JL(1991). Mononuclear cell trafficking and plasma protein extravasation into the CNS during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice. J Neurol Sci vol. 104, (1) 9-12.
10.1016/0022-510x(91)90209-p
Baker D, O'Neill JK, Amor S, Khamashta MA, Turk JL(1991). Inhibition of chronic relapsing experimental allergic encephalomyelitis in the mouse by the alkyl-lysophospholipid ET-18-OCH<inf>3</inf>. International Journal of Immunopharmacology vol. 13, (4) 385-392.
10.1016/0192-0561(91)90008-U
Watson CM, Davison AN, Baker D, O'Neill JK, Turk JL(1991). Suppression of demyelination by mitoxantrone. Int J Immunopharmacol vol. 13, (7) 923-930.
10.1016/0192-0561(91)90045-9
Wilcox CE, Ward AM, Evans A, Baker D, Rothlein R, Turk JL(1990). Endothelial cell expression of the intercellular adhesion molecule-1 (ICAM-1) in the central nervous system of guinea pigs during acute and chronic relapsing experimental allergic encephalomyelitis. J Neuroimmunol vol. 30, (1) 43-51.
10.1016/0165-5728(90)90051-N
Butter C, Healey DG, Baker D, Turk JL(1989). A quantitative immunocytochemical study of the infiltrating lymphocytes in the spinal cord of guinea pigs with chronic relapsing experimental allergic encephalomyelitis. J Neuroimmunol vol. 25, (2-3) 169-176.
10.1016/0165-5728(89)90134-3
Wilcox CE, Healey DG, Baker D, Willoughby DA, Turk JL(1989). Presentation of myelin basic protein by normal guinea-pig brain endothelial cells and its relevance to experimental allergic encephalomyelitis. Immunology vol. 67, (4) 435-440.
Wilcox CE, Baker D, Butter C, Willoughby DA, Turk JL(1989). Differential expression of guinea pig class II major histocompatibility complex antigens on vascular endothelial cells in vitro and in experimental allergic encephalomyelitis. Cell Immunol vol. 120, (1) 82-91.
10.1016/0008-8749(89)90176-7
BAKER D, PARKER DD, TURK JL(1985). Effect of depletion of epidermal dendritic cells on the induction of contact sensitivity in the guinea‐pig. British Journal of Dermatology vol. 113, (3) 285-294.
10.1111/j.1365-2133.1985.tb02080.x
BAKER D. Big conductance calcium-activated potassium channel openers control spasticity without sedation. British Journal of Pharmacology
10.1111/bph.13889
https://qmro.qmul.ac.uk/xmlui/handle/123456789/53704
MEIER U. Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis. Multiple Sclerosis and Related Disorders vol. 14, 46-50.
10.1016/j.msard.2017.03.013
https://qmro.qmul.ac.uk/xmlui/handle/123456789/22408
Return to top